ND0612, a formulation of levodopa/carbidopa delivered continuously under the skin by a pump, was more effective than standard oral levodopa/carbidopa at controlling motor symptoms of Parkinson’s disease without causing problematic side effects. Those top-line findings from the Phase 3 BouNDless clinical trial were announced earlier this year,…
Aspen Neuroscience will use Rune Labs’ digital health platform to remotely collect data from Parkinson’s disease patients currently enrolled in a screening study. The goal of the Trial-Ready Cohort Screening study is to provide a comprehensive view of the disease ahead of patient recruitment for Aspen’s…
P2B001, an investigational combination therapy (pramipexole/rasagiline) from Pharma Two B, controlled Parkinson’s disease symptoms better than either of its individual components regardless of patients’ age or disease severity, according to subgroup analyses from a Phase 3 trial. As with previous analyses involving all participants, P2B001 was as effective…
Gain Therapeutics’ GT-02287, an oral investigational therapy for Parkinson’s disease, was found to reduce blood levels of neurofilament light chain (NfL), a biomarker of nerve cell degeneration, in mouse models of the disorder. Further, the treatment lessened recognizable features associated with Parkinson’s symptoms — such as alpha-synuclein…
Treatment with the cell therapy bemdaneprocel (BRT-DA01) led to reductions in motor symptom severity for people with Parkinson’s disease in a small clinical trial, according to data announced by BlueRock Therapeutics, its developer. “We are excited to be sharing the results of this Phase I [trial] and look…
The Speech Accessibility Project continues to seek participants for its initiative, which focuses on enhancing voice recognition software for people facing speech difficulties like those associated with Parkinson’s disease. The project gathers voice recordings from people with Parkinson’s and related neurological conditions, such as multiple system atrophy…
Osteoporosis, a condition marked by fragile bones and very low bone mineral density (BMD), was associated with an increased risk of Parkinson’s disease in postmenopausal women, a new large-scale study in Korea found. In fact, “individuals with osteoporosis had a 1.40-fold higher HR [hazard ratio] … than those with…
Ventus Therapeutics has dosed the first participant in its Phase 1 trial testing VENT-02, a novel oral therapy that features an inhibitor that reaches the brain and targets NLRP3 — a protein that’s linked to brain inflammation in Parkinson’s disease. The trial aims to assess the safety and…
Adhering to healthy plant-based dietary patterns was associated with a reduced risk of developing Parkinson’s disease, especially among older people, according to a large-scale U.K. study. A higher intake of vegetables, nuts, and tea in the regular diet is linked to the lowest Parkinson’s risk, data show. “These results…
Exposure to alpha-synuclein, a protein that accumulates in the brains of Parkinson’s disease patients, led to inflammation and damage to nerve cells in the gut of mice carrying a human gene associated with several autoimmune disorders, a new study showed. Alpha-synuclein-related autoimmunity also induced constipation — a gut-related…
Get regular updates to your inbox.